it was great meeting you during the DS&AI event in Madrid. I'd be happy if you get in touch with me, ☕️ if you want to drink a coffee or 💊 if you want chat about digital transformation in chemical & pharmaceutical drug development 🐶🌎🧪📸 🧘‍♀️🏔️🧑‍🍳🚐 🍱

I've met Stefanie Schmittel during a DS&AI meeting in May 2023 in Madrid. She works within Data Strategy and Governance in the group Proprietary Information Management.

The Proprietary Information Management team, PIM, takes care of processes and systems related to either Compliance or Data Governance. Please talk to us if you need help with some cross-functional or collaboration-related topic or if you are interested to learn more about compound-related processes, compliance checks, lab notebook systems and similar things. For more information contact: Friederike Stoll.

The SCLM4Future project together with the PRINCE (Preclinical Information Center) project as well as the CONDAS (Connecting Data for Science) team is an excellent example for a successful cross-functional collaboration between CD&O, RED preMed and DS&AI within Research & Development but also between Platform IT and external partners. Together the team achieved to overcome legacy manual processes, redundant maintenance work, and functional silos by introducing new digital solutions and concepts with a strong collaborative mindset. The newly released SCLM 2.0 (Standard Codelist Maintenance) & PTO (Preclinical Terminology and Ontology) systems will enable our organization to improve the quality of controlled terminologies with regards to standard codelists and codes while reducing maintenance time and effort. This will have a positive impact on the code/codelist consistency across clinical and preclinical, as well as the compliance to regulatory requirements (e.g. CDISC (Clinical Data Interchange Standard Consortium) Controlled Terminology). The approach to share our knowledge as well as our efforts across functions will be an important step to archive our goals to increase data quality, interoperability and reusability – or to make a long story short: to make our data even more FAIR. For more information contact: Daniela Bergann.

Collaborations with external partners may lead to joint legal rights for compounds and data, which may restrict reusage in other projects. With the increasing number of collaborations at Bayer and with advancing time, memories of the project details fade, and reconstruction of the status will be nearly impossible. Therefore, we aim for a system to document the role of compounds, which will facilitate decisions on further usage in other collaborations. For more information contact: Miriam Wollenhaupt. Images taken from Microsoft Office free for use pictograms.

With the new head of R&D Community Engagement, RDCE, a new set-up has also been introduced, which newly regulates the tasks and responsibilities of the business partners assigned to the functions, SPOCs, which stands for Single Point of Contact. What is now in scope and what is not? The poster provides information on this.

Within DS&AI the Product Owner Hub team, POH, is here to drive the impact of digital products in R&D via a product-centric approach. We conduct this in a hub-and-spoke setting in close collaboration with our R&D colleagues and IT teams and we aim to increase the cross-functional and data-centric mindset throughout the organizations. Our team will establish a dynamic, holistic view on the R&D digital landscape through transparent and value-based digital product roadmaps. We will employ “total cost of ownership” principles that will allow us to better grasp the full cost of digital activities and systems for Bayer – and map this against the expected value. This should allow us to make jointly well-informed decisions about future digital investments investments closely working with our IT colleagues. Artwork created using Stable Diffusion.

ChemogenomicsDB (CGDB) and Älixir are prime examples of creating data assets and insight solutions to help improve digital and data capabilities, enhance scientific productivity, and invigorate early pipeline. Using our products, Bayer R&D colleagues can - access to a broad range of data assets essential for solving key drug discovery questions - explore integrated biomedical and chemical data for scientific curiosity, inspiration, and knowledge discovery - generate insights with the assistance of interactive visualizations for evidence-informed decision making